We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.37B
AUM Growth
+$301M
Cap. Flow
+$225M
Cap. Flow %
16.4%
Top 10 Hldgs %
27.24%
Holding
130
New
25
Increased
53
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$31.4M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$15.5M
3
COLL icon
Collegium Pharmaceutical
COLL
+$13M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.6M
5
ACHC icon
Acadia Healthcare
ACHC
+$10.7M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$22.5M
2
SRCL
Stericycle Inc
SRCL
+$10.3M
3
LH icon
Labcorp
LH
+$9.46M
4
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$7.97M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$6.9M

Sector Composition

Rank Sector Weight
1 Healthcare 76.77%
2 Financials 1.46%
3 Technology 0.96%
4 Industrials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$465B
$50.2M 3.66%
746,423
+146,423
+24% +$9.56M
MDT icon
2
Medtronic
MDT
$112B
$42.2M 3.08%
570,000
-2,300
-0.4% -$176K
BHC icon
3
Bausch Health
BHC
$1.75B
$42M 3.07%
189,250
+34,250
+22% +$7.59M
ACHC icon
4
Acadia Healthcare
ACHC
$2.52B
$40.1M 2.93%
511,750
+149,250
+41% +$10.7M
HCA icon
5
HCA Healthcare
HCA
$90.6B
$38.3M 2.8%
422,500
– –
AGN
6
DELISTED
Allergan plc
AGN
$36.9M 2.69%
121,500
+9,000
+8% +$2.68M
MCK icon
7
McKesson
MCK
$104B
$33.6M 2.45%
149,500
+500
+0.3% +$116K
ONCE
8
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$30.6M 2.24%
508,059
+474,953
+1,435% +$31.4M
GILD icon
9
Gilead Sciences
GILD
$165B
$30.1M 2.2%
257,500
+2,500
+1% +$273K
RDUS
10
DELISTED
Radius Health, Inc.
RDUS
$29M 2.12%
429,000
+29,000
+7% +$1.35M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$27.9M 2.04%
154,500
+46,250
+43% +$7.98M
PFE icon
12
Pfizer
PFE
$143B
$25.5M 1.86%
801,040
– –
HUM icon
13
Humana
HUM
$43.9B
$25.2M 1.84%
131,500
+24,000
+22% +$4.45M
AMGN icon
14
Amgen
AMGN
$209B
$23.9M 1.75%
156,000
-8,000
-5% -$1.28M
THOR
15
DELISTED
THORATEC CORPORATION
THOR
$23.7M 1.73%
532,500
+17,500
+3% +$766K
CELG
16
DELISTED
Celgene Corp
CELG
$22.9M 1.67%
198,000
+3,500
+2% +$400K
EVHC
17
DELISTED
Envision Healthcare Holdings Inc
EVHC
$22.5M 1.64%
190,380
– –
TVTX icon
18
Travere Therapeutics
TVTX
$5.17B
$22.4M 1.63%
675,000
-25,000
-4% -$685K
TMH
19
DELISTED
Team Health Holdings Inc
TMH
$20.4M 1.49%
312,500
+1,500
+0.5% +$90.6K
AET
20
DELISTED
Aetna Inc
AET
$19.9M 1.46%
156,500
– –
CI icon
21
Cigna
CI
$78.4B
$19.8M 1.44%
122,000
– –
LLY icon
22
Eli Lilly
LLY
$1.08T
$19.4M 1.42%
232,500
+2,500
+1% +$190K
NBIX icon
23
Neurocrine Biosciences
NBIX
$18.2B
$18M 1.31%
376,000
+1,000
+0.3% +$42.4K
CVS icon
24
CVS Health
CVS
$135B
$17.2M 1.26%
164,000
– –
ADAP
25
DELISTED
Adaptimmune Therapeutics
ADAP
$16.6M 1.21%
+905,000
New +$15.5M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Rock Springs Capital Management held 130 positions worth $1.37B, up 28% from $1.07B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $225M of net new capital in Q2 2015, opening 25 new positions and adding to 53 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 75% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $6.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2015 buy was Adaptimmune Therapeutics: 905,000 shares worth $16.6M.
  • Rock Springs Capital Management added most to Spark Therapeutics, Inc. Common Stock in Q2 2015, an estimated $31.4M increase.
  • Rock Springs Capital Management's biggest Q2 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $6.9M.
  • Rock Springs Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $22.5M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.37B portfolio in Q2 2015.
  • Rock Springs Capital Management opened 25 new positions and closed 13 in Q2 2015.
  • Rock Springs Capital Management's portfolio value rose 28% quarter-over-quarter to $1.37B.

Based on Rock Springs Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.